Profiling, Screening and full characterization of Lead Compounds
in vitro pharmacological profiling is being used earlier in the drug discovery process to identify desirable & undesirable off-target effects. Assessing your lead compounds specificity early on in the development phase using highly relevant and predictive assays allows you to make more informed decisions about your lead compounds safety. Ultimately this leads to the development of safer and more effective drugs at a lower cost down the road.
Specializing in both standard and custom in vitro assays, we are focused on providing the right assays for target identification & validation, assay development, screening, hit-to-lead validation to help identify candidate compounds for preclinical and clinical development.
Specializing in both standard and custom in vitro functional assays, we are focused on providing the right assays for assessing a GPCR therapeutic's potential efficacy and liabilities to help identify candidate compounds for preclinical and clinical development. Combined with our radioligand binding assays, these functional assays can provide an integrated assessment of a drug candidate's in vitro pharmacology profile.
METIS Labs offers a choice of microarrays that allow clients to screen ~45% to ~85% of the entire human proteome in a high throughput methodology. Radiolabeled samples interacting with immobilized proteins produce microscopic spots of varying intensity that we can detect with our digital imaging equipment.